Form 4: Klaviyo Co-CEO Sells Shares Under 10b5-1 Plan

Klaviyo Co-CEO Andrew Bialecki sold 200,000 shares of Series A Common Stock for approximately $3.7 million through a pre-arranged 10b5-1 trading plan.

Summary

• Andrew Bialecki, Co-Chief Executive Officer, Director, and 10% Owner of Klaviyo, Inc. (KVYO), reported transactions involving the company's stock.
• On March 3, 2026, Bialecki converted 200,000 shares of Series B Common Stock into 200,000 shares of Series A Common Stock.
• Immediately following the conversion, Bialecki sold all 200,000 shares of Series A Common Stock.
• The sales were executed in two tranches: 154,022 shares at a weighted average price of $18.86 per share (ranging from $18.22 to $19.21) and 45,978 shares at a weighted average price of $17.90 per share (ranging from $17.52 to $18.21).
• The total proceeds from these sales amounted to approximately $3,770,000.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Bialecki on May 20, 2025.
• Following these transactions, Bialecki directly holds 68,550,945 shares of Series B Common Stock and indirectly holds additional Series B shares through various trusts and his spouse.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it's an insider sale, the execution under a pre-arranged 10b5-1 plan reflects good governance and reduces concerns about opportunistic trading, indicating personal financial planning rather than a negative outlook on the company.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, adopted on May 20, 2025, which demonstrates structured personal financial planning and mitigates concerns about opportunistic insider trading.

Negatives

• The sale of 200,000 shares by a Co-CEO, Director, and 10% owner could be perceived by some investors as a reduction in direct equity exposure, although it was pre-planned.

Risks

• Potential for market misinterpretation of the insider sale, despite it being conducted under a Rule 10b5-1 plan, which could lead to short-term negative sentiment.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 trading plans are a common practice among corporate executives. These plans allow insiders to diversify their personal holdings or manage liquidity needs in a pre-scheduled manner, reducing the perception of trading on material non-public information. Such transactions are generally viewed as routine personal financial management rather than a signal about the company's immediate prospects.

Corporate Governance

Related Party Transactions

• Andrew Bialecki indirectly holds Series B Common Stock through The Andrew P. Bialecki Grantor Retained Annuity Trust I of 2023 (7,517,410 shares), The Elizabeth L. Bialecki Irrevocable GST Trust of 2023 (517,006 shares), The Andrew P. Bialecki Irrevocable GST Trust of 2023 (517,006 shares), and through his spouse (43,218 shares). The Reporting Person disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: May observe a reduction in direct equity holdings by a key executive, though the 10b5-1 plan mitigates concerns about the timing of the sale.

Key Dates

Recommendation

The Form 4 filing details a pre-arranged insider sale under a Rule 10b5-1 plan, which is a routine personal financial management event for executives. It does not provide new information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this disclosure alone does not alter the fundamental investment thesis for Klaviyo.

Keywords

Klaviyo, KVYO, Andrew Bialecki, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Series A Common Stock, Series B Common Stock, Executive Compensation